Tissue factor: Biological function and clinical significance

Saudi Medical Journal

Volumn 23, Issue 2, 2002, Pages 135-143

  Lwaleed, Bashir A ^a  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Assays clinical importance; Forms; Review; Tissue factor

Indexed keywords

CISPLATIN; CORTICOSTEROID; CYCLOSPORIN; DEXAMETHASONE; DOXORUBICIN; MEPREDNISONE; THROMBOPLASTIN;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING; CANCER; CELL CONTACT; CELL MEMBRANE; CIGARETTE SMOKING; CONTROLLED STUDY; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; FEMALE; GLOMERULONEPHRITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MACROPHAGE; MALE; METASTASIS; MONOCYTE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION; THROMBOPHILIA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH;

BLOOD COAGULATION; GLOMERULONEPHRITIS; HEMATOLOGIC TESTS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THROMBOPLASTIN;

EID: 0036125940     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Localization of human tissue factor antigen by immunostaining with monospecific, polychlonal anti-human tissue factor antibody
2. Stimulation of human leukocyte thromboplastic activity by endotoxin
3. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation
4. Immunohistochemical identification of tissue factor in solid tumours
5. The tissue factor pathway of blood coagulation
6. Tissue factor antigen levels in various biological fluids
7. Development and Validation of an assay for urinary tissue factor activity
8. Purification of human brain tissue factor
9. Affinity purification of human tissue factor. Interaction of factor VII and tissue factor in detergents micelles
10. Tissue factor revisited
11. Tissue Factor: Then and Now
12. A correlation between surface charge and coagulant action of phospholipids
13. Resolution if monomeric and heterodimeric forms of tissue factor, the high-affinity cellular receptor for factor VII
14. Characterization of a thrombomodulin cDNA reveals structural similarity to the low-density lipoprotein receptor
15. Comparative pharmacologic effects on tissue factor activity in normal cell and an established cell line
16. Association of tissue factor activity with the surface of cultured cells
17. The role of protein synthesis on the generation of tissue factor activity in leukocytes
18. Alterations to tissue factor that abolish activation of factor VII but maintain co-factor activity toward factor VIIa
19. Monocytes Vesiculation. A mechanism for dissemination of membrane-associated procoagulant activity and adhesion molecules after stimulation by LPS
20. Enhancement of mononuclear procoagulant activity by platelet 12-hydroxy-eicosatetraenoic acid
21. Lymphocytes co-operation is required for the amplification of macrophage procoagulant activity
22. Platelet activating factor enhancement of lipopolysaccharide-induce tissue factor activity in monocytes: Requirement of platelets and granulocytes
23. Macrophages and metastasis. A biological approach to cancer therapy. Presidential Address
24. The biology and tumour-related properties of monocyte tissue factor
25. Studien über die Bluterinnung mit besonderer Berücksichtigung der Haemophilie. I. Mitteilung: Einfluss des Harnes auf die Gerinnung haemophilen Blutes
26. Extraction and concentration of thromboplastic material from human urine
27. Urinary procoagulant excretion and its relation to kidney function
28. Urinary procoagulant behaves as tissue factor by promoting factor VIIa-catalyzed activation of factor X
29. The procoagulant in human urine: Purification, assay and some biochemical and physiological properties
30. Lipid vesicles and their association with procoagulant activity and glomeruli of rabbits with nephrotoxic nephritis
31. Concanavalin A inhibition of tissue factor (thromboplastin) activity
32. Urinary tissue factor activity in malignancy
33. Urinary tissue factor: A potential marker of disease
34. Fibrinolysis and coagulation markers in seminal plasma before and after vasectomy
35. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen
36. Preliminary findings of altered follicular activity in Holstein cows with coagulation XI deficiency
37. Potent blood coagulant activity of human semen due to prostosome-bound tissue factor
38. Ultrastructural localisation of the prostasome - An organelle in human seminal plasma
39. Immunosupression by human seminal plasma-extracellular organelles (prostosomes) modulate activity of phagocytic cells
40. Activation of coagulation factor X in human semen
41. The clinical value of tissue factor assays
42. The production and availability of tissue thromboplastin in cellular populations of whole blood exposed to various concentration of endotoxin: An assay for detection of endotoxin
43. Tissue factor activity in HeLa cells measured with a continuous chromogenic assay ELISA reader
44. Measurement of macrophage cellular procoagulant activity
45. Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes
46. The significance of measuring monocyte tissue factor in patients with breast and colorectal cancer
47. Shortened endotoxin-activated clotting time in patients with carcinoma
48. Possible role of platelet activating factor for tissue factor expression in macrophages and neutrophils
49. Increased monocyte tissue factor expression in coronary disease
50. Assessment of hyper-coagulability in patients with cancer using the Sonoclot Analyzer and Thromboelastography
51. Increased monocyte procoagulant activity with age
52. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex, and hormones replacement treatment
53. Monocyte tissue factor in malignancy
54. Detection of circulating tissue factor and factor VII in a normal population
55. Glucocorticoids inhibit the generation of leukocyte procoagulant (Tissue Factor) activity
56. Effect of some drugs on thromboplastin (factor III) activity of human monocytes in vitro
57. Modulation of tissue factor on human monocytes by cisplatin and adriamycin
58. Venous thrombosis during multimodal treatment of primary breast carcinoma
59. The influence of Tamoxifen in vivo on the main natural anticoagulants and fibrinolysis
60. Heparin kinetics: Variables related to disposition and dosage
61. Activation of factor XII by tobacco glycoprotein
62. White blood cell counts in persons age 65 years or more from the cardiovascular health study: Correlations with baseline clinical and demographic characteristics
63. Monocyte tissue factor expression is enhanced in women who smoke and use oral contraceptive
64. Tissue factor and hemostatsis
65. Tissue factor expression in endothelial cells in health and disease
66. Haemoglobin enhances the production of tissue factor by endothelial cells in response to bacterial endotoxin
67. Modulation of endothelial cell haemostatic properties by tumour necrosis factor
68. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity
69. Vascular Permeability Factor: A tumour derived-polypeptide which induces endothelial cell and monocyte procoagulant activity, and promotes monocytes migration
70. FDP-D-Dimer induces the secretion of interleukin-1, urokinase-type plasminogen activator inhibitor-2 in human promonocytic leukaemic cell line
71. Tissue factor antigen in senile plaques of Alzheimer's disease
72. Cholesterol and coronary heart disease. A new era
73. Spectrophotometry of tissue thromboplastin in cerebrospinal fluid
74. Use of human factor VIIa in the treatment of two haemophilia A patients with high-titer inhibitors
75. Tissue factor in cancer angiogenesis and metastasis
76. Tissue factor expression and metastatic potential of colorectal cancer
77. Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: Paracrine regulation by carcinoma cell-derived members of the transforming growth factor beta family
78. In situ detection of expression of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast tissue
79. The angiogenic effect of tissue factor on tumours and wounds
80. Tissue factor expression during human and mouse development
81. Tumour angiogenesis and tissue factor
82. Molecular mechanisms linking thrombosis and angiogenesis in cancer
83. Tissue factor controls the balance of angiogenic and antiangeogenic properties of tumor cells in mice
84. Tumour angiogenesis
85. Endotoxin induced expression of tumour necrosis factor, tissue factor plasminogen activator inhibitor activity by peritoneal macrophages
86. Regulation of extravascular coagulation by micro-vascular permeability
87. Tumour angiogenesis and metastasis-correlation in invasive breast carcinoma
88. Tissue factor expression in human non small cell lung carcinoma measured by immunohistochemistry: Correlation between tissue factor and angiogenesis
89. Stimulation of endothelial cell migration by VPF/VEGF through cooperative mechanisms involving the alphavbeta3 integrins, osteopontin and thrombin
90. Vascular permeability factor, fibrin, and the pathogenesis of tumour stroma formation
91. Hemostasis and malignancy
92. Role of platelets in tumour cell Metastases
93. Cancer procoagulant A: A factor X activating procoagulant from malignant tissue
94. Activation of blood coagulation in cancer: Trousseau's syndrome revisited
95. Coagulation and Cancer
96. Coagulative properties of cancer
97. Generation of procoagulant activity by mononuclear phagocytes: A possible mechanism contributing to blood clotting activation within malignant tissues
98. An assessment of monocytes procoagulant activity in patients with solid tumours
99. Tissue factor expression in breast cancer tissues: Its correlation with prognosis and plasma concentration
100. Platelet-tumour-cell-interactions in mice. The role of platelets in spread of malignant disease
101. Anti-metastatic effects associated with platelet reduction
102. Haemostatic abnormalities in malignancy, a prospective study of one hundred and eight patients. Part 1. Coagulation studies
103. Abnormalities of blood coagulation tests in patients with cancer
104. Monocyte procoagulant activity as a peripheral marker of clotting activation in cancer patients
105. Monocyte procoagulant activity in breast cancer
106. Increased monocyte procoagulant activity independent of the lupus anticoagulant in patients with systemic lupus erythematosus
107. Activation of coagulation and fibrinolysis in patients with lung cancer: Relation to tumour stage and prognosis
108. Monocyte tissue factor levels in cancer patients
109. Monocyte tissue factor in treated Hodgkin's disease
110. Monocyte production of thromboplastin activity in inflammatory and malignant diseases
111. A quantitative study on monocyte procoagulant activity in acute monoblastic and chronic myelomonoctic leukaemias
112. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: A clinical study
113. Lipoprotein associated coagulation inhibitor, factor VII, antithrombin III, and monocyte tissue factor following surgery
114. Structural and development of the glomerular crescent
115. Monocyte involvement in glomerular crescents. A histochemical and ultrastructural study
116. Role de l'hemostase dans la formation de croissants au cours des glomerulonephrites extracapillaries
117. Glomerular deposition of cross-linked fibrin in human kidney diseases
118. Is tissue factor a mediator of fibrin deposition in glomerular pathology?
119. Urinary procoagulant and fibrinolytic activity in human glomerulonephritis. Relationship with renal function
120. Urinary tissue factor levels in glomerulonephritis: A potential marker of glomerular injury